PF-AtlasКлинические испытания › NCT06572384

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Belimumab · Фаза 3

ID реестра
NCT06572384
Фаза
Фаза 3
Статус
Набор идет
Препарат / вмешательство
Belimumab
Спонсор
GlaxoSmithKline
Начало
2024-09-11
Набор участников
440
Центры
131

Об исследовании

Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.

Открыть NCT06572384 на ClinicalTrials.gov →

Связанные материалы

Связанные исследования

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT06572384 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.